FDA approves extension of Intercept Blood System to improve blood transfusion safety.- Cerus Corporation
Cerus Corporation, a biomedical products company focused on improving blood transfusion safety, announced FDA approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.
The INTERCEPT Blood System was initially approved by the FDA in December 2014 for treatment of platelets collected in a commercially available platelet additive solution, InterSol. Use of InterSol is already widespread in Europe; in the U.S., platelet additive solutions have been approved more recently and are still being introduced into blood center and hospital operations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins